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Abstract
Background: The purpose of this study is to investigate IL-1β regulation of a disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTS-4 and ADAMTS-5) expression through nuclear factor kappa B (NF-κB) in
human nucleus pulposus (NP) cells.
Methods: qRT-PCR and Western blot were used to measure ADAMTS expression. Transfections and gene silencing
were used to determine the role of NF-κB on cytokine-mediated ADAMTS expression and its role in aggrecan
degradation.
Results: IL-1β increased ADAMTS expression in NP cells. Treatment with NF-κB inhibitors abolished the inductive
effect of the cytokines on ADAMTS expression. Silencing of p65 confirmed their role in IL-1β-dependent ADAMTS-4
and ADAMTS-5 expression and aggrecan degradation.
Conclusions: By controlling the activation of NF-κB signaling, IL-1β modulates the expression of ADAMTS in NP
cells. To our knowledge, this is the first study that shows the contribution of both ADAMTS-4 and ADAMTS-5 to
aggrecan degradation in human NP cells.
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Introduction
The human intervertebral disc (IVD) is an important
component of the spinal column, and its dysfunction
leads to chronic low back pain (LBP) that affects 70 % of
people at some point in their lives [1]. The causes of low
back pain are multifactorial, although approximately
40 % of all cases involve degeneration of the interverte-
bral discs [2]. Intervertebral disc degeneration (IDD) is
characterized by the loss of the extracellular matrix
(ECM), whose major components are type II collagen
(Col II) and proteoglycans (PG) [3]. More importantly,
the loss of proteoglycan, predominantly aggrecan, is con-
sidered to be an early indicator of intervertebral disc de-
generation and therefore a reduced ability to resist
compressive load [4, 5]. Some previous studies have
demonstrated that the expression and activity of matrix-
degrading enzymes are increased and elicit degradation
of the aggrecan in the degenerative disc [6, 7].
There are two predominant matrix-degrading enzymes
that are able to hydrolyze aggrecan core proteins; these
are matrix metalloproteinases (MMPs) and aggrecanases
[8, 9]. There is evidence showing that there is increased
expression of MMPs in the cells from degenerated IVDs
[4, 10]. Although the MMPs are thought to play a role
in this process [11], it has been suggested that aggreca-
nases may also be involved, particularly since they par-
ticipate in the degradation of aggrecan in articular
cartilage and osteoarthritis (OA) [12, 13].
Aggrecanase belongs to a disintegrin and metallopro-
teinase with thrombospondin motifs (ADAMTS) family
and has the ability to degrade aggrecan. In this family,
ADAMTS-4 and ADAMTS-5 are also designated as
aggrecanase-1 and aggrecanase-2, respectively, because
they can specifically cleave cartilage proteoglycans.
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Previous studies focused on osteoarthritis, which shares
a similar pathogenesis with IVD degeneration, showing
that there is an upregulated expression of ADAMTS in
the degenerated articular cartilage [14, 15]. Unlike cartil-
age, in the nucleus pulposus (NP), both ADAMTS-4 and
ADAMTS-5 expressions are elevated in human degen-
erative disc disease [8, 16]. Surprisingly, despite the im-
portance of these ADAMTS in the pathogenesis of
osteoarthritis and disc disease, only a few studies have
investigated regulation of ADAMTS transcription in NP
cells [17, 18], and few have used human NP cells for
analysis. A clue to the mechanism lies in the finding
that, in animal NP cells, nuclear factor kappa B (NF-κB)
may contribute to TNF-α regulation of ADAMTS-4 and
ADAMTS-5 expression [19] and that TNF-α and IL-1β
also modulate ADAMTS-5 enzymatic activity through
syndecan-4 [20]. Although ADAMTS have been shown
to play a key role in articular cartilage and IDD, the cel-
lular mechanisms regulating ADAMTS gene expression
have, until now, not been explained. Antagonizing these
proteases can potentially retard degeneration and pre-
serve intervertebral disc tissue.
The pathogenesis of IVD degeneration is a complex
process and has a number of poorly understood bio-
logical and mechanical determinants [21]. These obser-
vations beg the questions of how IL-1β controls the
expression of ADAMTS-4 and ADAMTS-5 and what
their relative contributions in NP cells are in terms of
aggrecan degradation. In this study, we show for the first
time that IL-1β controls ADAMTS-4 and ADAMTS-5
transcription in a NF-κB-dependent fashion. Further-
more, our results show that ADAMTS-4 and ADAMTS-5
are non-redundant and that both play a role in the
cytokine-dependent degradation of aggrecan in human
NP cells. A therapeutic strategy can conceivably target
these enzymes for the structural preservation of the inter-
vertebral disc.
Materials and methods
Human NP cell isolation and culture
The study was approved by the Shanghai First People’s
Hospital Ethics Committee. All patients and their next
of kin signed an informed consent form allowing the re-
searchers to use IVD tissues obtained during spinal sur-
gery. All donor patients underwent spinal fusion surgery,
which requires the intervertebral disc to be resected. Pa-
tients were aged between 19 and 45 years old; mean age
was 30.52 years old. Only patients aged between 18 and
45 years old were included in this study. According to
the Pfirrmann grading scale [22], the discs were non-
degenerative (Pfirrmann < grade III) and degenerative
IVD tissue samples. All IVD tissues used in this study
would have been discarded as medical waste and would
not have been used in the patient’s treatment. Part of the
tissues was stored in liquid nitrogen for later use; the
second part was then directly sent to the cell culture la-
boratory super clean bench for primary culture of the
nucleus pulposus cells. NP tissues were washed three
times with phosphate-buffered saline (PBS; Gibco, USA),
minced into small fragments, and digested in 0.25 %
trypsin (Gibco, USA) and 0.2 % type II collagenase
(Gibco, USA) and then placed in PBS for approximately
3 h at 37 °C in a gyratory shaker. Cells were filtered
through a 70-μm mesh filter (BD, USA), and primary
NP cells were cultured with growth medium (Dulbecco’s
Modified Eagle’s Medium and Ham’s F-12 Nutrient
Mixture [DMEM-F12; Gibco, USA], 20 % fetal bovine
serum [FBS; Gibco, USA], 50 U/mL penicillin, 50 μg/mL
streptomycin (Gibco USA)) in a 100-mm culture dish in a
5 % CO2 incubator. The cells were treated in trypsin at ap-
proximately 80 % confluence and subcultured in a 60-mm
culture dish (2.5 × 105 cells/well). All experiments in this
study used first- or second-generation cells.
Cell treatment
Human non-degenerative NP cells were grown to con-
fluence in 60-mm culture dishes, underwent serum
starvation overnight to synchronize the cell cycles, and
were stimulated with 0~20 ng/mL recombinant human
IL-1β (Peprotech, London, UK) for 24 h, and the cata-
bolic response and NF-κB activation were observed. To
justify the effectiveness of the NF-κB inhibitor, cells were
pretreated with various concentrations of BAY11-7082
(Sigma-Aldrich, St. Louis, MO, USA) (2.5 μM, 5.0 μM) for
1 h, followed by treatment for 48 h with IL-1β (10 ng/mL)
and BAY11-7082. Cells were then harvested for messenger
ribonucleic acid (mRNA) and protein analysis.
Immunofluorescence microscopy
The first-generation NP cells were plated in flat-bottom
24-well plates (5 × 103/well) and were fixed with 4 %
paraformaldehyde, permeabilized with 0.2 % Triton-X
100 in PBS for 10 min, blocked with PBS containing
5 % FBS, and incubated with antibodies against p65
(1:200) at 4 °C overnight. As a negative control, cells
were reacted with isotype IgG under similar conditions.
After washing, the cells were incubated with anti-rabbit
secondary antibody (Jackson, USA) at a dilution of
1:200 for 1 h at room temperature. Cells were imaged
using a laser scanning confocal microscope (Olympus
Fluoview, Japan).
Lentivirus infection
Lentivirus (8 × 108 TU/mL) packaging of green fluores-
cent protein (GFP) LV-shp65 and negative control (NC)
were constructed in Genechem (Shanghai, China). Cells
(1 × 103) were plated onto 96-well plates 48 h before the
LV-shp65 and negative control were added to infected
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NP cells at various volumes to determine the best MOI
value at which concentrations have no virus toxicity
effect on cells. Ninety-six hours after infection, the GFP
gene expression was observed under a fluorescence
microscope, and the infected cells were collected for si-
lencing treatment. Then, cells were harvested for protein
extraction at 5 days after viral transduction. The experi-
ment was repeated three times.
Gene expression analysis
Total RNA was extracted from the NP cells and NP tis-
sues by TRIzol (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. The mRNA was ana-
lyzed with real-time polymerase chain reaction (PCR)
using the ABI 7500 Fast real-time PCR system (Applied
Biosystems, Carlsbad, CA). cDNA was then reverse tran-
scribed (Thermo, USA) according to the manufacturer’s
instructions. Real-time PCR reactions were done in trip-
licate in 96-well plates using a SYBR Premix Ex Taq Kit
(TaKaRa, Dalian, China) with a final volume of 20 μL.
All primers (Table 1, obtained from Sangon, Shanghai,
China) were designed based on coding sequences. The
cycle threshold values were obtained, and data were
normalized to β-actin expression using the 2−ΔΔCt
method [23].
Western blot analysis
Nucleocytoplasmic separation and RIPA Kit were used
for extraction of the nuclear protein and total protein,
supplemented with phosphatase inhibitors and protease
inhibitor cocktail (Biotech Well, Shanghai, China). Ly-
sates were centrifuged for 20 min at 12,000g. The pro-
tein concentration was determined using the BCA
protein assay (Beyotime, Jiangsu, China), and equivalent
amounts of protein (40 μg) were separated by electro-
phoresis on sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto poly-
vinylidene fluoride (PVDF) membranes. After being
blocked in Tris-buffered saline Tween-20 (TBS-T) with
5 % milk powder (2 h), it was then incubated with the
specific antibody for NF-κB p65 (Epitomics, USA) and
antibodies for ADAMTS-4, ADAMTS-5, and aggrecan
(Abcom, Hong Kong, China) at 4 °C with gentle shaking
overnight. After washing, membranes were incubated with
the respective secondary antibody (Jackson, USA) at the
appropriate concentration for 2 h at room temperature.
Immunolabeling was done using enhanced chemilu-
minescence (ECL) reagents (Amersham Biosciences,
Roosendaal, Netherlands).
Statistical analysis
The SPSS 17.0 software (SPSS Inc., Chicago, USA) was
used for statistical calculations. Student’s t test and ana-
lysis of variance were used for comparisons between the
different groups. All experiments were repeated three
times with cells from different IVD tissues, and for each
experimental condition, the experiment was repeated
three times; the data is represented as mean ± standard
deviation. The findings were considered to be statisti-
cally significant when P < 0.05.
Results
Analysis for the expression of p65 protein in human NP
tissue and NP cells
NF-κB activity was confirmed by p65 immunoblotting
of nuclear extracts (Fig. 1a): Western blots clearly
showed that the p65 band in the nuclear extract of
degenerated disc samples is increased compared with
non-degenerated disc samples, while non-degenerated
samples showed a much smaller amount of target pro-
tein. When compared to the non-degenerated group,
expression of p65 protein in the degenerative group in-
creases with an increase in the degree of degeneration
of the IVD. Immunoreactivity for p65 was observed in
both non-degenerated and degenerated human NP
cells. In the degenerated human NP cells, the specific
p65 antibody detected p65 in the nucleus (which is
indicative of active NF-κB), while non-degenerated
human NP cells show the cytoplasmic location of p65
(which is indicative of non-active NF-κB) (Fig. 1b).
Gene expression of ADAMTS-4, ADAMTS-5, and aggrecan
in human intervertebral discs
ADAMTS-4, ADAMTS-5, and aggrecan mRNA were
expressed in the nucleus pulposus of both non-
degenerated and degenerated human intervertebral
discs. When we compared the expression levels of the
target genes, a statistically significant increase in the
gene expression of ADAMTS-4 and ADAMTS-5 was
seen in degenerated disc samples compared with non-
degenerated disc samples (P < 0.05) (Fig. 2a). A corre-
sponding decrease was seen in the aggrecan gene




P65 Forward: 5′ TGCATCCACAGTTTCCAGAAC 3′
Reverse: 5′ CACGCTGCTCTTCTTGGAAGG 3′
ADAMTS-4 Forward: 5′ ACTGGTGGTGGCAGATGACA3′
Reverse: 5′ TCACTGTTAGCAGGTAGCGCTTT3′
ADAMTS-5 Forward: 5′ GCTTCTATCGGGGCACAGT3′
Reverse: 5′ CAGCAGTGGCTTTAGGGTGTAG3′
β-actin Forward: 5′ AGCGAGCATCCCCCAAAGTT3′
Reverse: 5′ GGGCACGAAGGCTCATCATT3′
ADAMTS a disintegrin and metalloprotease with thrombospondin motifs
Sun et al. Journal of Orthopaedic Surgery and Research  (2015) 10:159 Page 3 of 9
expression in degenerated intervertebral discs com-
pared with non-degenerated samples (Fig. 2b).
Expression of ADAMTS-4 and ADAMTS-5 is regulated by
IL-1β in human NP cells
The expression of ADAMTS-4 and ADAMTS-5 in hu-
man NP cells was studied using real-time PCR and
Western blot analysis. To explore the premise that IL-1β
concerned with disc degeneration regulates ADAMTS-4
and ADAMTS-5 expression, human NP cells were
treated with IL-1β, and the expression of ADAMTS-4
and ADAMTS-5 was analyzed. Treatment with IL-1β re-
sulted in a dose-dependent increase in ADAMTS-4 and
ADAMTS-5 mRNA levels (Fig. 3a, b). In addition, we
measured the level of ADAMTS-4 and ADAMTS-5 pro-
tein in a conditioned medium of treated NP cells by
Western blot analysis. IL-1β treatment significantly in-
creased ADAMTS-4 and ADAMTS-5 protein expression
in human NP cells (Fig. 4). To determine if IL-1β pro-
moted ADAMTS activity, we measured the generation
of aggrecan. A significant decrease in aggrecan gener-
ation is detected when cells were treated with IL-1β
compared with untreated cells (Figs. 3c and 4).
IL-1β promotes ADAMTS-4 and ADAMTS-5 expression
through activation of NF-κB signaling
To determine whether NF-κB signaling is required for
the cytokine-dependent induction of ADAMTS-4 and
ADAMTS-5 in human NP cells, we first evaluated the
activation of NF-κB signaling pathways after treatment
with IL-1β. After treatment with IL-1β, there was a
rapid increase in p65 nucleoprotein levels (Fig. 5a). To
ascertain whether the IL-1β-induced expression of
ADAMTS-4 and ADAMTS-5 requires NF-κB signal-
ing, human NP cells were pretreated with pathway-
specific inhibitors. Pretreatment caused a significant
suppression in the IL-1β induction of both ADAMTS-
4 and ADAMTS-5 mRNA levels (Fig. 6a, b). Similarly,
a pronounced decrease in the IL-1β-mediated increase
in the levels of the ADAMTS-4 and ADAMTS-5 pro-
tein was seen in the presence of NF-κB pathway inhibi-
tors (Fig. 5b). Importantly, we examined the effect of
ADAMTS-4 and ADAMTS-5 expression on aggrecan
degradation in human NP cells. Suppression of ADAMTS-
4 and ADAMTS-5 expression resulted in a significant
inhibition of IL-1β-mediated aggrecan degradation in hu-
man NP cells (Figs. 5b and 6c).
Fig. 1 NF-κB activity was confirmed in the intervertebral disc. Part a shows increased levels of p65 in nuclear extracts upon degenerated disc samples
compared with non-degenerated samples. Data were obtained by p65 immunoblotting of nuclear extracts (n= 3), and one representative sample is
shown. Part b demonstrates that non-degenerated human NP cells show cytoplasmic localization of p65 (indicative of non-active NF-κB), while
degenerated human NP cells show nuclear localization of p65 (which is indicative of active NF-κB). Data were obtained by immunocytochemistry for
p65 (n = 2), and one representative sample is shown. Histone H3 is used as a loading control
Sun et al. Journal of Orthopaedic Surgery and Research  (2015) 10:159 Page 4 of 9
Both ADAMTS-4 and ADAMTS-5 contribute to IL-1β-induced
aggrecan degradation in human NP Cells
Given that IL-1β regulates ADAMTS-4 and ADAMTS-5
expression using NF-κB signaling pathways, we per-
formed lentiviral-mediated gene silencing studies. We
first silenced the expression of NF-κB p65 and then
measured ADAMTS-4 and ADAMTS-5 expression in
human NP cells. In human NP cells transduced with
plasmid shp65, there was a significant decrease in the
mRNA levels of p65, compared with cells transduced
with control shRNA (Fig. 7a). Importantly, suppression
of the NF-κB p65 component significantly blocked the in-
ductive effect of IL-1β on the expression of ADAMTS-4
and ADAMTS-5 protein and mRNA levels, as well as
aggrecan degradation (Fig. 7b, c and Fig. 8).
Discussion
The experiments described in this investigation demon-
strated for the first time that expression of ADAMTS-4
and ADAMTS-5, two important enzymes concerned
with aggrecan degradation, is regulated by the inflamma-
tory cytokine IL-1β through the NF-κB signaling path-
ways in human NP cells. A second major observation is
that, by regulating ADAMTS-4 and ADAMTS-5 expres-
sion and activity, IL-1β controlled aggrecan turnover.
Importantly, both ADAMTS-4 and ADAMTS-5 were re-
quired for the cytokine-dependent aggrecan degradation
in human NP cells, and their function appears to be
non-redundant, suggesting a possible role in interverte-
bral disc pathologies.
According to our gene expression studies, the results
demonstrated for the first time that ADAMTS-4 and
ADAMTS-5 mRNA are present in both non-degenerated
and degenerated human intervertebral discs. When we
compared the expression levels of the ADAMTS genes, a
statistically significant increase in the gene expression of
ADAMTS-4 and ADAMTS-5 was seen in degenerated
disc samples compared to non-degenerated disc samples.
The fact that expression is seen in non-degenerated discs
could indicate a possible role for the ADAMTS enzymes
in the normal turnover of aggrecan. Although ADAMTS-
4 and ADAMTS-5 are considered chiefly in terms of
aggrecan catabolism [24], it is involved with a number of
diverse physiological functions. Moreover, the mechanism
of regulation of expression is incompletely understood in
human intervertebral disc. Some studies have reported
that the expression of ADAMTS-4 and ADAMTS-5 is
upregulated by IL-1β in chondrocytes and fibroblasts
[25, 26]. In the present study, treatment of human NP
cells with IL-1β clearly induced ADAMTS-4 and
ADAMTS-5 expression. These results are consistent with
previous reports that the inflammatory cytokines induce
ADAMTS-4 and ADAMTS-5 mRNA expression in the
NP [17, 20, 27]. Although the mechanism is unknown,
there is some evidence to indicate that TNF-α-dependent
ADAMTS-4 expression and aggrecanase activity in the
NP may be regulated by NF-κB signaling [19].
The activation of the transcription factor NF-κB leads
to an upregulation of proinflammatory cytokines and
matrix-degrading enzymes [28–30]. We therefore inves-
tigated the NF-κB signaling activity in the human inter-
vertebral disc. The findings of Western blot on nuclear
extracts and immunofluorescence showed that the nu-
clear translocation of p65 correlated with degeneration.
We suspected that NF-κB signaling might also be in-
volved in the process of IVD degeneration. Indeed,
chronic activation of NF-κB is associated with numer-
ous diseases, including musculo-skeletal diseases such
as osteoarthritis, osteoporosis, rheumatoid arthritis,
and muscular dystrophy [31–34]. The study clearly
showed that the treatment of human nucleus pulposus
cells with IL-1β induced nuclear translocation of the
p65 expression. We confirmed that IL-1β promoted
Fig. 2 a, b The use of RT-PCR for the detection of ADAMTS-4,
ADAMTS-5, and aggrecan mRNA expression on nucleus pulposus
tissue. Values are represented as mean ± standard deviation (n = 6).
P < 0.05 is considered as statistically significant. ADAMTS a disintegrin
and metalloproteinase with thrombospondin motifs, Agg aggrecan,
G2 grade 2 Pfirrmann, G3 grade 3 Pfirrmann, G4 grade 4 Pfirrmann,
G5 grade 5 Pfirrmann. *P < 0.05 vs. control
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NF-κB activation and that the signaling pathways con-
trolled ADAMTS-4 and ADAMTS-5 expression. To fur-
ther investigate whether the expression of ADAMTS-4
and ADAMTS-5 is mediated by NF-κB following IL-1β
stimulation, BAY11-7082, a specific inhibitor of NF-κB,
was added to the medium before IL-1β treatment. As
expected, BAY11-7082 significantly reversed the effect of
IL-1β on the accumulation of NF-κB and the expression of
ADAMTS-4 and ADAMTS-5, therefore causing a recov-
ery of aggrecan content in human NP cells.
In further support for the role of NF-κB in ADAMTS-4
and ADAMTS-5 regulation are loss-of-function transfec-
tion studies that measured the expression of ADAMTS-4
and ADAMTS-5. The silencing studies that demonstrated
the inhibition of IL-1β-dependent ADAMTS-4 and
ADAMTS-5 expression after suppression of NF-κB-p65
signaling highlight the importance of this pathway in con-
trolling ADAMTS-4 and ADAMTS-5 expression.
Fig. 3 Expression and cytokine dependency of ADAMTS-4, ADAMTS-5, and aggrecan in human NP cells. a, b RT-PCR analysis of ADAMTS-4 and
ADAMTS-5 expression by human NP cells treated with IL-1β. There was a dose-dependent increase in ADAMTS-4 and ADAMTS-5 mRNA expression by
the cytokine treatment. c Treatment of human NP cells with IL-1β resulted in a significant decrease of aggrecan. Data are expressed as mean ± SD from
six independent experiments. *P < 0.05 vs. control
Fig. 4 Western blot analysis of NP cells indicates increased expression
of ADAMTS-4, ADAMTS-5, and aggrecan after IL-1β treatment. Data
showed are representative of three independent experiments using
different samples, and one representative sample is shown
Fig. 5 Modulation of IL-1β-dependent expression of ADAMTS-4
and ADAMTS-5 expression by NF-κB signaling in human NP cells. a
Western blot analysis of p65 nucleoproteins after treatment of NP
cells with IL-1β. b Western blot analysis indicates that treatment
with NF-κB inhibitor completely abolished ADAMTS-4 and
ADAMTS-5 protein induction by IL-1β and the level of aggrecan
was significantly increased. Data are expressed as mean ± SD
from three independent experiments
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Moreover, the silencing of the NF-κB-p65 signaling path-
way that connects ADAMTS-4 and ADAMTS-5 expres-
sion had a negative effect on aggrecan degradation in cells
of the human NP. These results of the functional
studies indicate that by controlling the activity of NF-
κB-p65 signaling, we may modulate the expression of
ADAMTS-4 and ADAMTS-5 in human NP cells. We
speculate that the loss of aggrecan has been attrib-
uted to the action of the NF-κB pathway and plays a
key role in IVD degradation.
Fig. 6 a–c Inhibition of NF-κB signaling resulted in a significant blocking of IL-1β-dependent induction in ADAMTS-4, ADAMTS-5, and aggrecan
mRNA expression. Data are normalized with β-actin and are expressed as ratio to control cells. Control cell value = 1. Values are mean ± SD
(n = 6 samples). *P < 0.05 vs. IL-1β alone; #P < 0.05 vs. control
Fig. 7 Regulation of ADAMTS-4 and ADAMTS-5 expression by NF-κB. a qRT-PCR analysis of cells transduced with control lentivirus LV-shC and LV-shp65.
b, c qRT-PCR analysis of ADAMTS-4, ADAMTS-5, and aggrecan in human NP cells infected with LV-shC and LV-shp65. Note that the IL-1β-dependent
increase in ADAMTS-4, ADAMTS-5, and aggrecan levels is significantly increased by suppression of the component of the NF-κB-p65 signaling pathway.
Data are expressed as mean ± SD from six independent experiments. *P< 0.05 vs. IL-1β alone; #P< 0.05 vs. control
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Conclusion
In conclusion, the current study suggests that NF-κB
plays a major role in the pathway of the pathogenesis of
IVD degeneration, leading to upregulation of ADAMTS
and degradation of the disc matrix macromolecule
aggrecan. We found that antagonism of NF-κB activity
by genetic depletion or pharmacologic inhibition can
abolish upregulation of ADAMTS-4 and ADAMTS-5
and consequently reverse the degradation of aggrecan.
For the reason that inhibiting NF-κB activation may
contribute to the pathogenesis of human diseases, such
as disc degeneration, the suppression of NF-κB activity
may represent a useful molecular target for the treat-
ment of the NF-κB-linked human diseases.
Abbreviations
ADAMTS: A disintegrin and metalloproteinase with thrombospondin motifs;
Col II: type II collagen; ECL: enhanced chemiluminescence; ECM: extracellular
matrix; IDD: intervertebral disc degeneration; IVD: human intervertebral disc;
LBP: low back pain; MMPs: matrix metalloproteinases; mRNA: messenger
ribonucleic acid; NF-κB: nuclear factor kappa B; NP: nucleus pulposus;
OA: osteoarthritis; PG: proteoglycans.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZYS wrote the manuscript and designed the study, ZY did the experimental
work and designed the study, CL did the experimental work and the
statistical analysis, HL reviewed the manuscript and designed the study, MJ
supervised the project and did the statistical analysis, and JT was responsible
for the whole project and supervised the study. All authors read and
approved the final manuscript.
Acknowledgements
We would like to thank Dr. Yoshvin Sunnassee for his invaluable help and
advice in drafting and correcting the manuscript. There were no sources of
funding for this article.
Author details
1Department of Orthopedics, School of Medicine, Shanghai General Hospital
Affiliated to Shanghai Jiao Tong University, 100, Haining Road, Shanghai
200080, China. 2Spine and Joint Surgery, Central Hospital of Tai An,
Shandong, China.
Received: 13 June 2015 Accepted: 19 September 2015
References
1. Cathy Speed. Low back pain. BMJ. 2004;328:1119–21.
2. Luoma K, Riihimäki H, Luukkonen R, Raininko R, Viikari-Juntura E, Lamminen
A. Low back pain in relation to lumbar disc degeneration. Spine (Phila Pa
1976). 2000;25(4):487–92.
3. Phillips KL, Jordan-Mahy N, Nicklin MJ, Le Maitre CL. Interleukin-1 receptor
antagonist deficient mice provide insights into pathogenesis of human
intervertebral disc degeneration. Ann Rheum Dis. 2013;72:11.
4. Pockert AJ, Richardson SM, Le Maitre CL, Lyon M, Deakin JA, Buttle DJ, et al.
Modified expression of the ADAMTS enzymes and tissue inhibitor of
metalloproteinases 3 during human intervertebral disc degeneration. Arthritis
Rheum. 2009;60:2.
5. Furtwängler T, Chan SC, Bahrenberg G, Richards PJ, Gantenbein-Ritter B.
Assessment of the matrix degenerative effects of MMP-3, ADAMTS-4, and
HTRA1, injected into a bovine intervertebral disc organ culture model. Spine
(Phila Pa 1976). 2013;38:22.
6. Zeldich E, Koren R, Dard M, Weinberg E, Weinreb M, Nemcovsky CE. Enamel
matrix derivative induces the expression of tissue inhibitor of matrix
metalloproteinase-3 in human gingival fibroblasts via extracellular signal-
regulated kinase. J Periodontal Res. 2010;45:2.
7. Verma P, Dalal K. ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis.
J Cell Biochem. 2011;112:12.
8. Patel KP, Sandy JD, Akeda K, Miyamoto K, Chujo T, An HS, et al. Aggrecanases
and aggrecanase-generated fragments in the human intervertebral disc at
early and advanced stages of disc degeneration. Spine (Phila Pa 1976).
2007;32:23.
9. Zhang Q, Hui W, Litherland GJ, Barter MJ, Davidson R, Darrah C, et al.
Differential Toll-like receptor-dependent collagenase expression in
chondrocytes. Ann Rheum Dis. 2008;67:11.
10. Gruber HE, Ingram JA, Hoelscher GL, Zinchenko N, Norton HJ, Hanley Jr EN.
Matrix metalloproteinase 28, a novel matrix metalloproteinase, is constitutively
expressed in human intervertebral disc tissue and is present in matrix of more
degenerated discs. Arthritis Res Ther. 2009;11(6):R184. doi:10.1186/ar2876.
Epub 2009 Dec 9.
11. Carlos LO, Lavanya HP, Yardena S. Protective roles of matrix
metalloproteinases: from mouse models to human cancer. Cell Cycle.
2009;8:3657.
12. Matsukawa T, Sakai T, Yonezawa T, Hiraiwa H, Hamada T, Nakashima M, et al.
MicroRNA-125b regulates the expression of aggrecanase-1 (ADAMTS-4) in
human osteoarthritic chondrocytes. Arthritis Res Ther. 2013;15(1):R28.
13. Yamamoto K, Owen K, Parker AE, Scilabra SD, Dudhia J, Strickland DK, et al.
Low density lipoprotein receptor-related protein 1
(LRP1)-mediated endocytic clearance of a disintegrin and metalloproteinase
with thrombospondin motifs-4 (ADAMTS-4): functional differences of
non-catalytic domains of ADAMTS-4 and ADAMTS-5 in LRP1 binding. J Biol
Chem. 2014;289(10):6462-74.
14. Lim NH, Kashiwagi M, Visse R, Jones J, Enghild JJ, Brew K, et al. Reactive-site
mutants of N-TIMP-3 that selectively inhibit ADAMTS-4 and ADAMTS-5:
biological and structural implications. Biochem J. 2010;431(1):113–22.
15. Troeberg L, Nagase H. Proteases involved in cartilage matrix degradation in
osteoarthritis. Biochim Biophys Acta. 2012;1824:133.
16. Hatano E, Fujita T, Ueda Y, Okuda T, Katsuda S, Okada Y et al. Expression of
ADAMTS-4 (aggrecanase-1) and possible involvement in regression of
lumbar disc herniation. Spine (Phila Pa 1976). 2006;31(13):1426–32.
17. Lee JM, Song JY, Baek M, Jung HY, Kang H, Han IB, et al. Interleukin-1β
induces angiogenesis and innervation in human intervertebral disc
degeneration. J Orthop Res. 2011;29(2):265–9.
18. Mwale F, Masuda K, Pichika R, Epure LM, Yoshikawa T, Hemmad A, et al. The
efficacy of Link N as a mediator of repair in a rabbit model of intervertebral
disc degeneration. Arthritis Res Ther. 2011;13(4):R120.
19. Séguin CA, Bojarski M, Pilliar RM, Roughley PJ, Kandel RA. Differential
regulation of matrix degrading enzymes in a TNFalpha-induced model of
nucleus pulposus tissue degeneration. Matrix Biol. 2006;25(7):409–18.
20. Wang J, Markova D, Anderson DG, Zheng Z, Shapiro IM, Risbud MV. TNF-α
and IL-1β promote a disintegrin-like and metalloprotease with
Fig. 8 ADAMTS-4 and ADAMTS-5 promote aggrecan degradation
in human NP cells. Western blot analysis of human NP cells
infected with control lentivirus (LV-shC) and lentivirus expressing
shRNA NF-κB-p65. Data are expressed as mean ± SD from three
independent experiments
Sun et al. Journal of Orthopaedic Surgery and Research  (2015) 10:159 Page 8 of 9
thrombospondin type I motif-5 mediatedaggrecan degradation through
syndecan-4 in intervertebral disc. J Biol Chem. 2011;286(46):39738–49.
21. Freemont AJ, Watkins A, Le Maitre C, Jeziorska M, Hoyland JA. Current
understanding of cellular and molecular events in intervertebral disc
degeneration: implications for therapy. J Pathol. 2002;196(4):374–9.
22. Pfirrmann CW, Metzdorf A, Zanetti M, Hodler J, Boos N. Magnetic resonance
classification of lumbar intervertebral disc degeneration. Spine (Phila Pa
1976). 2001;26(17):1873–8.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods.
2001;25:402.
24. Moncada-Pazos A, Obaya AJ, Viloria CG, López-Otín C, Cal S. The
nutraceutical flavonoid luteolin inhibits ADAMTS-4 and ADAMTS-5
aggrecanase activities. J Mol Med (Berl). 2011;89(6):611–9.
25. Yamamoto K, Troeberg L, Scilabra SD, Pelosi M, Murphy CL, Strickland DK, et
al. LRP-1-mediated endocytosis regulates extracellular activity of ADAMTS-5
in articular cartilage. FASEB J. 2013;27(2):511–21. doi:10.1096/fj.12-216671.
Epub 2012 Oct 11.
26. Yatabe T, Mochizuki S, Takizawa M, Chijiiwa M, Okada A, Kimura T et al.
Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human
osteoarthritic chondrocytes. Ann Rheum Dis. 2009;68(6):1051–8.
27. Tsuji T, Chiba K, Imabayashi H, Fujita Y, Hosogane N, Okada Y, et al. Age-
related changes in expression of tissue inhibitor of metalloproteinases-3
associated with transition from the notochordal nucleus pulposus to the
fibrocartilaginous nucleus pulposus in rabbit intervertebral disc. Spine (Phila
Pa 1976). 2007;32(8):849–56.
28. Wuertz K, Quero L, Sekiguchi M, Klawitter M, Nerlich A, Konno Set ss. The
red wine polyphenol resveratrol shows promising potential for the
treatment of nucleus pulposus-mediated pain in vitro and in vivo. Spine
(Phila Pa 1976). 201;36(21):E1373–84.
29. Tian Y, Yuan W, Fujita N, Wang J, Wang H, Shapiro IM et al. Inflammatory
cytokines associated with degenerative disc disease control aggrecanase-1
(ADAMTS-4)expression in nucleus pulposus cells through MAPK and NF-κB.
Am J Pathol. 2013;182(6):2310–21.
30. Nasto LA, Seo HY, Robinson AR, Tilstra JS, Clauson CL, Sowa GA et al. ISSLS
prize winner: inhibition of NF-κB activity ameliorates age-associated disc
degeneration in a mouse model of accelerated aging. Spine (Phila Pa 1976).
2012;37(21):1819–25.
31. Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB. NF-kappaB signaling:
multiple angles to target OA. Curr Drug Targets. 2010;11(5):599–613.
32. Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IkappaB kinase (IKK) inhibitor,
NEMO-binding domain peptide, blocks osteoclastogenesis and bone
erosion in inflammatory arthritis. J Biol Chem. 2004;279(36):37219-22. Epub
2004 Jul 13.
33. Kim HJ, Chang EJ, Kim HM, Lee SB, Kim HD, Su Kim G, et al. Antioxidant
alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear
factor-kappaB DNA bindingand prevents in vivo bone resorption induced
by receptor activator of nuclear factor-kappaB ligand and tumor necrosis
factor-alpha. Free Radic Biol Med. 2006;40(9):1483–93.
34. Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, et
al. Interplay of IKK/NFkappaB signaling in macrophages and myofibers
promotes muscle degeneration inDuchenne muscular dystrophy. J Clin
Invest. 2007;117(4):889–901.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sun et al. Journal of Orthopaedic Surgery and Research  (2015) 10:159 Page 9 of 9
